To describe health related quality of life (HRQOL) and symptoms in the SPIRIT trial and determine effects of implantable cardioverter defibrillator (ICD) shocks on HRQOL over 24 months. Ninety participants aged 66 ± 10 years, 96% men, 75% with NYHA class II, with an ICD were randomized to spironolactone 25 mg (N = 44) or placebo (N = 46). HRQOL was measured every 6 months for 24 months using: Patient Concerns Assessment (PCA), Short Form Health Survey-Veterans Version (SF-36V), and Kansas City Cardiomyopathy Questionnaire (KCCQ). Linear mixed modeling compared changes in HRQOL over-time and ANCOVA compared HRQOL between those getting an ICD shock or not. Over 24-months, there were no differences in HRQOL between the spironolactone versus placebo groups. Those with at least one ICD shock reported significantly lower HRQOL and more symptoms at 6- and 24-months. Patients receiving one or more ICD shocks reported significant reductions in HRQOL and higher symptoms.
BoixelC.GavilletB.RougierJ. S.AbrielH. (2006). Aldosterone increases voltage-gated sodium current in ventricular myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 290(6), H2257–H2266.
2.
CevikC.Perez-VerdiaA.NugentK. (2009). Implantable cardioverter defibrillators and their role in heart failure progression. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology, 11(6), 710–715.
3.
ChevalierP.CottrauxJ.MollardE.SaiN.BrunS.BurriH.RestierL.AdeleineP. (2006). Prevention of implantable defibrillator shocks by cognitive behavioral therapy: A pilot trial. American Heart Journal, 151(1), 191–191.e6.
4.
ConnollyS. J.DorianP.RobertsR. S.GentM.BailinS.FainE. S.ThorpeK.ChampagneJ.TalajicM.CoutuB.GronefeldG. C.HohnloserS. H. (2006). Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial. JAMA, 295(2), 165–171.
5.
FordJ.LittletonH.LutesL.WuenschK.BentonC.CahillJ.HudsonC.NekkantiR.GehiA.SearsS. (2019). Evaluation of an Internet-based intervention for ICD patients with elevated symptoms of posttraumatic stress disorder. Pacing and Clinical Electrophysiology, 42(5), 521–529.
6.
GordonA. C.MasonA. J.ThirunavukkarasuN.PerkinsG. D.CecconiM.CepkovaM.PogsonD. G.AyaH. D.AnjumA.FrazierG. J.SanthakumaranS.AshbyD.BrettS. J.; for the VANISH Investigators. (2016). Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial. JAMA, 316(5), 509–518.
7.
GreenC. P.PorterC. B.BresnahanD. R.SpertusJ. A. (2000). Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. Journal of the American College of Cardiology, 35(5), 1245–1255. http://www.ncbi.nlm.nih.gov/pubmed/10758967
8.
HayashiM.TsutamotoT.WadaA.TsutsuiT.IshiiC.OhnoK.FujiiM.TaniguchiA.HamataniT.NozatoY.KataokaK.MorigamiN.OhnishiM.KinoshitaM.HorieM. (2003). Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation, 107(20), 2559–2565.
9.
HsuJ.UratsuC.TrumanA.QuesenberryC.McDonaldK. M.HlatkyM. A.SelbyJ. (2002). Life after a ventricular arrhythmia. American Heart Journal, 144(3), 404–412.
10.
HuntS. A.AbrahamW. T.ChinM. H.FeldmanA. M.FrancisG. S.GaniatsT. G.JessupM.KonstamM. A.ManciniD. M.MichlK.OatesJ. A.RahkoP. S.SilverM. A.StevensonL. W.YancyC. W.; American College of Cardiology Foundation, & American Heart Association. (2009). 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. Journal of the American College of Cardiology, 53(15), e1–e90.
11.
IrvineJ.DorianP.BakerB.O’BrienB. J.RobertsR.GentM.NewmanD.ConnollyS. J. (2002). Quality of life in the Canadian implantable defibrillator study (CIDS). American Heart Journal, 144(2), 282–289.
12.
JenkinsL. S.DunbarS. B.HawthorneM. H. (1997). Patient concerns before and the first 9-months after ICD implantation. Circulation, 96(8), 745–745.
13.
JordanJ.TitscherG.PeregrinovaL.KirschH. (2013). Manual for the psychotherapeutic treatment of acute and post-traumatic stress disorders following multiple shocks from implantable cardioverter defibrillator (ICD). Psycho-Social Medicine, 10, Doc09.
14.
KamphuisH. C.De LeeuwJ. R.DerksenR.HauerR.WinnubstJ. A. (2002). A 12-month quality of life assessment of cardiac arrest survivors treated with or without an implantable cardioverter defibrillator. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology, 4(4), 417–425.
15.
KasamaS.ToyamaT.KumakuraH.TakayamaY.IchikawaS.SuzukiT.KurabayashiM. (2003). Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 41(4), 574–581.
16.
KazisL. E.RenX. S.LeeA.SkinnerK.RogersW.ClarkJ.MillerD. R. (1999). Health status in VA patients: Results from the veterans health study. American Journal of Medical Quality, 14(1), 28–38.
17.
KloppeA.ProclemerA.ArenalA.LunatiM.Martìnez FerrerJ. B.HersiA.GulajM.WijffelsM. C.SantiE.ManottaL.MangoniL.GaspariniM. (2014). Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: Data from the avoid delivering therapies for nonsustained arrhythmias in ICD patients III (ADVANCE III) trial. Circulation, 130(4), 308–314.
18.
KurtzS. M.OchoaJ. A.LauE.ShkolnikovY.PavriB. B.FrischD.GreensponA. J. (2010). Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993-2006. Pacing and Clinical Electrophysiology, 33(6), 705–711.
19.
LewisE. F.KimH. Y.ClaggettB.SpertusJ.HeitnerJ. F.AssmannS. F.KenwoodC. T.SolomonS. D.DesaiA. S.FangJ. C.McKinlayS. A.PittB. A.PfefferM. A.; TOPCAT Investigators. (2016). Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation Heart Failure, 9(3), e001937.
20.
MarkD. B.AnstromK. J.SunJ. L.Clapp-ChanningN. E.TsiatisA. A.Davidson-RayL.LeeK. L.BardyG. H.; Sudden Cardiac Death in Heart Failure Trial Investigators. (2008). Quality of life with defibrillator therapy or amiodarone in heart failure. The New England Journal of Medicine, 359(10), 999–1008.
21.
MoradiM.DaneshiF.BehzadmehrR.RafiemaneshH.BouyaS.RaeisiM. (2020). Quality of life of chronic heart failure patients: A systematic review and meta-analysis. Heart Failure Reviews, 25(6), 993–1006.
22.
MossA. J.SchugerC.BeckC. A.BrownM. W.CannomD. S.DaubertJ. P.EstesNa3rdGreenbergHHallW. JHuangD. TKautznerJKleinHMcNittSOlshanskyBShodaMWilberDZarebaW; MADIT-RIT Trial Investigators. (2012). Reduction in inappropriate therapy and mortality through ICD programming. The New England Journal of Medicine, 367(24), 2275–2283.
23.
NoyesK.CoronaE.ZwanzigerJ.HallW. J.ZhaoH.WangH.MossA. J.DickA. W.; Multicenter Automatic Defibrillator Implantation Trial II. (2007). Health-related quality of life consequences of implantable cardioverter defibrillators: Results from MADIT II. Medical Care, 45(5), 377–385.
24.
PassmanR.SubaciusH.RuoB.SchaechterA.HowardA.SearsS. F.KadishA. (2007). Implantable cardioverter defibrillators and quality of life: Results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Archive of Internal Medicine, 167(20), 2226–2232.
25.
PerrierE.KerfantB. G.LaleveeN.BideauxP.RossierM. F.RichardS.GómezA. M.BenitahJ. P. (2004). Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation, 110(7), 776–783.
26.
PittB.PfefferM. A.AssmannS. F.BoineauR.AnandI. S.ClaggettB.ClausellN.DesaiA. S.DiazR.FlegJ. L.GordeevI.HartyB.HeitnerJ. F.KenwoodC. T.LewisE. F.O’MearaE.ProbstfieldJ. L.ShaburishviliT.ShahS. J.. . . McKinlayS. M.; TOPCAT Investigators. (2014). Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine, 370(15), 1383–1392.
27.
PittB.RemmeW.ZannadF.NeatonJ.MartinezF.RonikerB.BittmanR.HurleyS.KleimanJ.GatlinM. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine, 348(14), 1309–1321.
28.
PittB.ZannadF.RemmeW. J.CodyR.CastaigneA.PerezA.PalenskyJ.WittesJ. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine, 341(10), 709–717.
29.
RedheadA. P.TurkingtonD.RaoS.TynanM. M.BourkeJ. P. (2010). Psychopathology in postinfarction patients implanted with cardioverter-defibrillators for secondary prevention. A cross-sectional, case-controlled study. Journal of Psychosomatic Research, 69(6), 555–563.
30.
SchronE. B.ExnerD. V.YaoQ.JenkinsL. S.SteinbergJ. S.CookJ. R.KutalekS. P.FriedmanP. L.BubienR. S.PageR. L.PowellJ. (2002). Quality of life in the antiarrhythmics versus implantable defibrillators trial: Impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation, 105(5), 589–594.
31.
SearsS. F.RosmanL.SasakiS.KondoY.SternsL. D.SchlossE. J.KuritaT.MeijerA.RaijmakersJ.GerritseB.AuricchioA. (2018). Defibrillator shocks and their effect on objective and subjective patient outcomes: Results of the PainFree SST clinical trial. Heart Rhythm, 15(5), 734–740.
32.
SearsS. F.SowellL. D.KuhlE. A.KovacsA. H.SerberE. R.HandbergE.KneippS. M.ZinehI.ContiJ. B. (2007). The ICD shock and stress management program: A randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing and Clinical Electrophysiology, 30(7), 858–864.
33.
StamblerB. S.LauritaK. R.ShroffS. C.HoekerG.MartovitzN. L. (2009). Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm, 6(6), 776–783.
34.
TomzikJ.KoltermannK. C.ZabelM.WillichS. N.ReinholdT. (2015). Quality of life in patients with an implantable cardioverter defibrillator: A systematic review. Frontiers in Cardiovascular Medicine, 2, 34.
35.
WareJ.; New England Medical Center Hospital. Health Institute. (1994). SF-36 physical and mental health summary scales: A user’s manual. Health Institute, New England Medical Center.
36.
WongF. M. F.SitJ. W. H.WongE. M. L.ChoiK. C. (2014). Factors associated with health-related quality of life among patients with implantable cardioverter defibrillator: Identification of foci for nursing intervention. Journal of Advanced Nursing, 70(12), 2821–2834.
37.
YardımcıT.MertH. (2019). Web-based intervention to improve implantable cardioverter defibrillator patients’ shock-related anxiety and quality of life: A randomized controlled trial. Clinical Nursing Research, 28(2), 150–164.
38.
ZannadF.McMurrayJ. J.KrumH.van VeldhuisenD. J.SwedbergK.ShiH.VincentJ.PocockS. J.PittB.; EMPHASIS-HF Study Group. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine, 364(1), 11–21.
39.
ZarragaI. G. E.DoughertyC. M.MacMurdyK. S.RaittM. H. (2012). The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. Circulation: Arrhythmia and Electrophysiology, 5(4), 739–747.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
